Enlivex Therapeutics Ltd.
ENLV · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $24,001 | $50,151 | $72,476 | $111,623 |
| - Cash | $3,301 | $813 | $47,822 | $11,202 |
| + Debt | $534 | $1,032 | $4,847 | $617 |
| Enterprise Value | $21,234 | $50,370 | $29,501 | $101,038 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$545 | -$835 | -$777 | -$546 |
| % Margin | – | – | – | – |
| EBITDA | -$14,469 | -$28,219 | -$25,020 | -$18,742 |
| % Margin | – | – | – | – |
| Net Income | -$15,014 | -$29,068 | -$31,060 | -$14,468 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.73 | -1.56 | -2.31 | -0.54 |
| % Growth | 53.2% | 32.5% | -327.8% | – |
| Operating Cash Flow | -$13,008 | -$23,523 | -$23,953 | -$17,542 |
| Capital Expenditures | -$103 | -$236 | -$8,122 | -$1,625 |
| Free Cash Flow | -$13,111 | -$23,759 | -$32,075 | -$19,167 |